Trial Profile
An open-label study to evaluate the pharmacokinetics of Raltegravir in healthy female volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 05 Dec 2015 New trial record